Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study

医学 黄斑变性 脉络膜新生血管 视力 随机对照试验 不利影响 眼科 临床终点 外科 内科学
作者
Kun Liu,Yanping Song,Gezhi Xu,Jian Ye,Zhifeng Wu,Xiaoling Liu,Xiao-guang Dong,Mingzhi Zhang,Yiqiao Xing,Shaoping Zhu,Xia Chen,Yinchen Shen,Hengye Huang,Liyun Yu,Zunhong Ke,Philip J. Rosenfeld,Peter K. Kaiser,Gui‐Shuang Ying,Xiaodong Sun,Xun Xu
出处
期刊:American Journal of Ophthalmology [Elsevier BV]
卷期号:197: 156-167 被引量:158
标识
DOI:10.1016/j.ajo.2018.08.026
摘要

Purpose

Age-related macular degeneration (AMD) can cause irreversible vision loss leading to blindness. We aim to evaluate the efficacy and safety of intravitreal injections of 0.5 mg conbercept, a new anti–vascular endothelial growth factor (anti-VEGF) drug, for treatment of AMD on a schedule more manageable for patients.

Design

A prospective, double-masked, multicenter, sham-controlled, phase III randomized trial.

Methods

Patients: Patients with choroidal neovascularization (CNV) secondary to AMD were enrolled and randomized to the conbercept group or the sham control group. Intervention: The conbercept group received intravitreal injections of conbercept (0.5 mg) once monthly for the first 3 months, then once quarterly until month 12 (3 + Q3M). The sham group received first 3 monthly sham injections and then 3 monthly injections of conbercept (0.5 mg) followed by quarterly administrations until month 12. Main Outcome Measures: The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA) at month 3.

Results

A total of 114 patients (91.9%) from 9 sites in China completed the 12-month study. At the 3-month primary endpoint, the mean changes in BCVA from baseline were +9.20 letters in the conbercept group and +2.02 letters in the sham group, respectively (P < .001). At 12 months, the mean changes from baseline in BCVA letter score were +9.98 letters in the conbercept group and +8.81 letters in the sham group (P = .64). The most common ocular adverse events were associated with intravitreal injections, such as conjunctival hemorrhage, and increased intraocular pressure.

Conclusions

A conbercept dosing regimen of 3 initial monthly administrations followed by quarterly treatments is effective for treatment of AMD. In previous reports, other anti-VEGF agents were unable to maintain similar clinical benefits with the same regimen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
xpc发布了新的文献求助30
1秒前
1秒前
欧阳镇东发布了新的文献求助10
1秒前
科研通AI6.2的应助被优美的剑采纳,获得10
1秒前
钉钉123456完成签到,获得积分10
1秒前
桐桐的应助被jiangsuway采纳,获得10
2秒前
七十三度发布了新的文献求助10
2秒前
2秒前
现代的听云完成签到,获得积分20
2秒前
科研通AI6.3的应助被111采纳,获得10
2秒前
dd99081完成签到,获得积分10
2秒前
XING发布了新的文献求助20
3秒前
rice发布了新的文献求助10
3秒前
3秒前
3秒前
dolphin完成签到,获得积分10
3秒前
3秒前
悦耳十三发布了新的文献求助10
3秒前
3秒前
kangzezhou完成签到,获得积分10
4秒前
ju00完成签到,获得积分10
4秒前
微兔小妹完成签到 ,获得积分10
5秒前
5秒前
小苏打完成签到 ,获得积分10
5秒前
周勇军完成签到,获得积分10
5秒前
369ninja发布了新的文献求助10
6秒前
小k完成签到,获得积分10
6秒前
小煜发布了新的文献求助10
6秒前
山丘完成签到,获得积分10
7秒前
orixero的应助被675675采纳,获得10
7秒前
RWcreator完成签到 ,获得积分10
7秒前
Pomelo完成签到,获得积分10
7秒前
7秒前
LLL发布了新的文献求助10
7秒前
Wedg完成签到 ,获得积分10
8秒前
8秒前
XuNan完成签到,获得积分10
8秒前
youyouka完成签到,获得积分20
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185